Síndrome de diferenciación en paciente con leucemia promielocítica aguda: importancia de la TC de tórax

Gorospe Sarasúa, Luis; Ventura-Díaz, Sofía; Ayala-Carbonero, Ana María; Gambí-Pisonero, Esther; Sánchez-Tornero de la Cruz, Adrián; Pérez-Lamas, Lucía; Mirambeaux-Villanova, Rosa Mariela; Chinea-Rodríguez, Anabelle.
Arch. bronconeumol. (Ed. impr.) ; 56(5): 326-327, mayo 2020. ilus
Artículo en Español | IBECS (España) | ID: ibc-198127

Documentos relacionados

  1. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
  2. Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
  3. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
  4. Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
  5. The simpler, the better: oral arsenic for acute promyelocytic leukemia.
  6. Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia.
  7. Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
  8. Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
  9. Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid.
  10. Cup-shaped nuclei in acute promyelocytic leukaemia.